Frédéric Pamoukdjian1, Thierry Bouillet2, Vincent Lévy3, Michael Soussan4, Laurent Zelek2, Elena Paillaud5. 1. APHP, Avicenne Hospital, Geriatric Department, Coordination Unit in Geriatric Oncology, F-93000, Bobigny, France; Université Paris 13, Sorbonne Paris Cité, Health Education and Practices Laboratory (LEPS EA3412), F-93017, Bobigny, France. Electronic address: frederic.pamoukdjian@aphp.fr. 2. APHP, Avicenne Hospital, Department of Medical Oncology, F-93000, Bobigny, France. 3. APHP, Avicenne Hospital, Clinical Research Unit/Clinical Research Center, F-93000, Bobigny, France. 4. APHP, Avicenne Hospital, Department of Radiology, F-93000, Bobigny, France. 5. APHP, Henri-Mondor Hospital, Geriatric Department, Geriatric Oncology Unit, F-94000, Créteil, France; Université Paris-Est, UPEC, DHU A-TVB, IMRB- EA 7376 CEpiA (Clinical Epidemiology And Ageing Unit), F-94000, Créteil, France.
Abstract
BACKGROUND & AIMS: To assess the prevalence of sarcopenia before cancer treatment and its predictive value during the treatment. METHODS: We searched MEDLINE via PubMed for articles published from 2008 to 2016 that reported prospective observational or interventional studies of the prevalence of pre-therapeutic sarcopenia and its consequences in adults with cancer who were 18 years or older. Two independent reviewers selected articles based on titles and/or abstracts before a complete review. Sarcopenia had to be measured before cancer treatment. Methods recommended by consensuses (CT scan, MRI, dual X-ray absorptiometry or bio-impedancemetry) to assess sarcopenia were considered. Characteristics of the studies included the prevalence of pre-therapeutic sarcopenia and the prognostic value for outcomes during the cancer treatment. RESULTS: We selected 35 articles involving 6894 participants (in/out patients, clinical trials). The mean age ranged from 53 to 69.6 years. Pre-therapeutic sarcopenia was found in 38.6% of patients [95% CI 37.4-39.8]. Oesophageal and small-cell lung cancers showed the highest prevalence of pre-therapeutic sarcopenia. Pre-therapeutic sarcopenia was significantly and independently associated with post-operative complications, chemotherapy-induced toxicity and poor survival in cancer patients. CONCLUSIONS: Pre-therapeutic sarcopenia is highly prevalent in cancer patients and has severe consequences for outcomes of cancer patients.
BACKGROUND & AIMS: To assess the prevalence of sarcopenia before cancer treatment and its predictive value during the treatment. METHODS: We searched MEDLINE via PubMed for articles published from 2008 to 2016 that reported prospective observational or interventional studies of the prevalence of pre-therapeutic sarcopenia and its consequences in adults with cancer who were 18 years or older. Two independent reviewers selected articles based on titles and/or abstracts before a complete review. Sarcopenia had to be measured before cancer treatment. Methods recommended by consensuses (CT scan, MRI, dual X-ray absorptiometry or bio-impedancemetry) to assess sarcopenia were considered. Characteristics of the studies included the prevalence of pre-therapeutic sarcopenia and the prognostic value for outcomes during the cancer treatment. RESULTS: We selected 35 articles involving 6894 participants (in/out patients, clinical trials). The mean age ranged from 53 to 69.6 years. Pre-therapeutic sarcopenia was found in 38.6% of patients [95% CI 37.4-39.8]. Oesophageal and small-cell lung cancers showed the highest prevalence of pre-therapeutic sarcopenia. Pre-therapeutic sarcopenia was significantly and independently associated with post-operative complications, chemotherapy-induced toxicity and poor survival in cancerpatients. CONCLUSIONS: Pre-therapeutic sarcopenia is highly prevalent in cancerpatients and has severe consequences for outcomes of cancerpatients.
Authors: Minji Jang; Hyung Woo Park; Jimi Huh; Jong Hwa Lee; Yoong Ki Jeong; Yang Won Nah; Jisuk Park; Kyung Won Kim Journal: Eur Radiol Date: 2018-11-07 Impact factor: 5.315
Authors: Gabriel F P Aleixo; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini; Grant R Williams Journal: Oncologist Date: 2019-11-12
Authors: Utku Oflazoglu; Ahmet Alacacioglu; Umut Varol; Yuksel Kucukzeybek; Tarik Salman; Halil Taskaynatan; Yasar Yildiz; Ozlem Ozdemir; MustafaOktay Tarhan Journal: Support Care Cancer Date: 2019-06-03 Impact factor: 3.603
Authors: Leon Lenchik; Kristin M Lenoir; Josh Tan; Robert D Boutin; Kathryn E Callahan; Stephen B Kritchevsky; Brian J Wells Journal: J Gerontol A Biol Sci Med Sci Date: 2019-06-18 Impact factor: 6.053
Authors: Saro H Armenian; Meisi Xiao; Jennifer Berano Teh; Brandyn Lee; Howard A Chang; Kristen Mascarenhas; Sean Lee; Alex Iukuridze; Jack J Xie; Jessica M Scott; Lee W Jones; F Lennie Wong; Stephen J Forman; Ryotaro Nakamura Journal: J Natl Cancer Inst Date: 2019-08-01 Impact factor: 13.506
Authors: Utku Oflazoglu; Ahmet Alacacioglu; Umut Varol; Yuksel Kucukzeybek; Tarik Salman; Halil Taskaynatan; Yasar Yildiz; Seray Saray; M Oktay Tarhan Journal: Support Care Cancer Date: 2019-11-22 Impact factor: 3.603